Elevation Oncology Analyst Ratings
Elevation Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 941.45% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 09/29/2023 | 212.43% | HC Wainwright & Co. | → $1.5 | Initiates Coverage On | → Buy |
| 06/05/2023 | 1149.74% | Wedbush | $4 → $6 | Maintains | Outperform |
| 05/30/2023 | 1566.32% | SVB Securities | $5 → $8 | Upgrades | Market Perform → Outperform |
| 03/10/2023 | 733.16% | Wedbush | → $4 | Reiterates | → Outperform |
| 01/09/2023 | 108.29% | SVB Leerink | $2 → $1 | Maintains | Market Perform |
| 11/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/07/2022 | 316.58% | SVB Leerink | $11 → $2 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1462.17% | HC Wainwright & Co. | → $7.5 | Assumes | → Buy |
| 08/08/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/04/2022 | 4274.09% | Wedbush | $27 → $21 | Maintains | Outperform |
| 12/23/2021 | 2399.48% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/20/2021 | 5523.83% | Wedbush | → $27 | Initiates Coverage On | → Outperform |
| 07/20/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/20/2021 | 4065.8% | SVB Leerink | → $20 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/06/2023 | 941.45% | Wedbush | → 5 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 09/29/2023 | 212.43% | HC Wainwright & Co. | → 1.5 美元 | 启动覆盖范围开启 | → 购买 |
| 06/05/2023 | 1149.74% | Wedbush | 4 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 05/30/2023 | 1566.32% | SVB 证券 | 5 美元 → 8 美元 | 升级 | 市场表现 → 跑赢大盘 |
| 03/10/2023 | 733.16% | Wedbush | → 4 美元 | 重申 | → 跑赢大盘 |
| 01/09/2023 | 108.29% | SVB Leerink | $2 → $1 | 维护 | 市场表现 |
| 2022 年 10 月 11 日 | — | 摩根大通 | 降级 | 中性 → 体重不足 | |
| 2022 年 7 月 11 日 | 316.58% | SVB Leerink | 11 美元 → 2 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 09/19/2022 | 1462.17% | HC Wainwright & Co. | → 7.5 美元 | 假设 | → 购买 |
| 08/08/2022 | — | 摩根大通 | 降级 | 超重 → 中性 | |
| 03/04/2022 | 4274.09% | Wedbush | 27 美元 → 21 美元 | 维护 | 跑赢大盘 |
| 12/23/2021 | 2399.48% | HC Wainwright & Co. | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 7 月 20 日 | 5523.83% | Wedbush | → 27 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 7 月 20 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2021 年 7 月 20 日 | 4065.8% | SVB Leerink | → 20 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Elevation Oncology (ELEV)?
Elevation Oncology（ELEV）的目标价格是多少？
The latest price target for Elevation Oncology (NASDAQ: ELEV) was reported by Wedbush on November 6, 2023. The analyst firm set a price target for $5.00 expecting ELEV to rise to within 12 months (a possible 941.45% upside). 8 analyst firms have reported ratings in the last year.
Wedbush于2023年11月6日公布了Elevation Oncology（纳斯达克股票代码：ELEV）的最新目标股价。该分析公司将目标股价定为5.00美元，预计ELEV将在12个月内升至12个月内（可能上涨941.45％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Elevation Oncology (ELEV)?
Elevation Oncology (ELEV) 的最新分析师评级是多少？
The latest analyst rating for Elevation Oncology (NASDAQ: ELEV) was provided by Wedbush, and Elevation Oncology reiterated their outperform rating.
Wedbush提供了Elevation Oncology（纳斯达克股票代码：ELEV）的最新分析师评级，Elevation Oncology重申了其跑赢大盘的评级
When is the next analyst rating going to be posted or updated for Elevation Oncology (ELEV)?
Elevation Oncology (ELEV) 的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Elevation Oncology的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Elevation Oncology的最新评级是在2023年11月6日发布的，因此您应该预计下一个评级将在2024年11月6日左右公布。
Is the Analyst Rating Elevation Oncology (ELEV) correct?
分析师评级提升肿瘤学 (ELEV) 是否正确？
While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a reiterated with a price target of $0.00 to $5.00. The current price Elevation Oncology (ELEV) is trading at is $0.48, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Elevate Oncology（ELEV）评级得到了重申，目标股价为0.00美元至5.00美元。目前Elevation Oncology（ELEV）的交易价格为0.48美元，在分析师的预测范围内。